Grufity logo
Grufity logo
ONTX

ONTX - Onconova Therapeutics Inc Stock Price, Fair Value and News

$12.34-3.32 (-21.20%)
Delayed as of 14 Sep 2026, 04:00 pm ET

ONTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ONTX Price Action

Last 7 days

8.6%

Last 30 days

-33.6%

Last 90 days

1123.4%

Trailing 12 Months

765.2%

ONTX RSI Chart

ONTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ONTX Valuation

Market Cap

189.6M

Price/Earnings (Trailing)

-8.79

Price/Sales (Trailing)

131.32

EV/EBITDA

-22.57

Price/Free Cashflow

-11.26

ONTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ONTX Fundamentals

ONTX Revenue

Revenue (TTM)

2.8M

Rev. Growth (Yr)

-100%

ONTX Earnings

Earnings (TTM)

-21.6M

Earnings Growth (Yr)

-233.77%

Earnings Growth (Qtr)

57.03%

ONTX Profitability

EBT Margin

-579.32%

Return on Equity

-1.3K%

Return on Assets

-188.02%

Free Cashflow Yield

-8.88%

ONTX Investor Care

Shares Dilution (1Y)

117.40%

Diluted EPS (TTM)

-1.79

Revenue & Growth

How Onconova Therapeutics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025867.0K1.5M2.1M2.8M
2024226.0K226.0K226.0K226.0K
2023226.0K226.0K226.0K226.0K
2022226.0K226.0K226.0K226.0K
2021235.0K236.0K227.0K226.0K
20202.2M201.0K204.0K231.0K
20191.5M1.7M1.9M2.2M
20181.1M1.3M1.3M1.2M
20174.3M2.4M817.0K787.0K
201612.8M14.9M15.0M5.5M
2015467.0K465.0K2.0M11.5M
20144.1M3.6M2.6M800.0K
201346.8M47.5M5.8M4.8M
201212.7M23.8M35.0M46.2M
2011---1.5M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Onconova Therapeutics Inc

ONTX
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
 CEO
 WEBSITEonconova.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES16

Onconova Therapeutics Inc Frequently Asked Questions

ONTX is the stock ticker symbol of Onconova Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of Onconova Therapeutics Inc is 189.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, ONTX's PE ratio (Price to Earnings) is -8.79 and Price to Sales (PS) ratio is 131.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ONTX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Onconova Therapeutics Inc has provided -0.5 (multiply by 100 for percentage) rate of return.